Health TrialsbyHealthPanel

Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery

ConditionsPancreatic CancerPancreatic NeoplasmLiver Metastases
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-99
SponsorUniversity of Aarhus

About this trial

The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board

No liver metastases on CT

At least 18 years old and able to provide informed consent

Expected pancreatic ductal adenocarcinoma based on CT scan

Disqualifiers

Metastatic disease

Prior receipt of neoadjuvant chemotherapy or downstaging/-sizing treatment

Comorbidity rendering major surgery unfeasible (inoperable)

No informed consent

Trial design

Design model

Single group

Treatments tested in this trial

  • Preoperative MRI

    Diagnostic test

    Preoperative MRI performed between outpatient visit at the surgical clinic and scheduled date of resection

Treatment groups

200 Participants
are divided into 1 treatment group
Group A: Preoperative MRIExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Change in treatment strategy

Change in treatment strategy from intended curative resection to other treatment based on MRI scan

Time frame
1 week

Secondary outcomes

1

Liver metastases

Proportion of patients who had liver metastases detected on MRI

Time frame
1 week
2

Surgery

Proportion of patients who made it to surgery/exploration

Time frame
1 month
3

Resection

Proportion of patients in each arm who had a pancreatic resection performed

Time frame
1 month
4

Intraoperatively detected liver metastases

Proportion of patients with intraoperatively detected liver metastases not seen on either CT or MRI.

Time frame
1 month

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Aarhus

Lead sponsor

Rigshospitalet, Denmark

Collaborator

Aalborg University Hospital

Collaborator

Source ClinicalTrials.gov
Apply now